Successful “Date Certain M&A” of Tarsa Therapeutics, Inc. its Assets and Intellectual Property – Gerbsman Partners, Financial Advisor |
Steven R. Gerbsman, Principal of Gerbsman Partners and Kenneth Hardesty, a member of Gerbsman Partners Board of Intellectual Capital announced today their success in maximizing value for the assets and Intellectual Property of Tarsa Therapeutics, Inc. Tarsa is an NDA-ready company focused on advancing it lead product, TBRIA. TBRIA is a proprietary oral formulation containing recombinant salmon calcitonin for the treatment of postmenopausal osteoporosis.
Gerbsman Partners provided Financial Advisory leadership to Tarsa, through its proprietary Date Certain M&A Process, facilitated the sale of the business unit’s assets and its associated Intellectual Property and closing of the sale. Due to market conditions, the board of directors of Tarsa made the strategic decision to maximize the value of the business unit and Intellectual Property. Gerbsman Partners provided leadership to the company with:
About Gerbsman Partners Gerbsman Partners focuses on maximizing enterprise value for stakeholders and shareholders in under-performing, under-capitalized and under-valued companies and their Intellectual Property. Since 2001, Gerbsman Partners has been involved in maximizing value for 103 technology, medical device, life science, solar, fuel cell, cyber security, consumer and digital marketing companies and their Intellectual Property and has restructured/terminated over $810 million of real estate executory contracts and equipment lease/sub-debt obligations. Since inception in 1980, Gerbsman Partners has been involved in over $2.3 billion of financings, restructurings and M&A transactions. Gerbsman Partners has offices and strategic alliances in San Francisco, Orange County, Boston, New York, Washington, DC, McLean, VA, Europe and Israel. |
Successful “Date Certain M&A” of Tarsa Therapeutics, Inc. its Assets and Intellectual Property – Gerbsman Partners, Financial Advisor
February 20, 2018 by Steven R. Gerbsman
Leave a Reply